Ann Optom Contact Lens > Volume 25(2); 2026 > Article
Zhang: Defocus Spectacle Lenses for Myopia Control in Children: Design, Fitting, Compliance, and Long-term Outcomes

Abstract

The global prevalence of childhood myopia is escalating, necessitating effective and non-invasive interventions to mitigate axial elongation and associated pathologies. Defocus spectacle lenses (DSLs), a category encompassing technologies such as Defocus Incorporated Multiple Segments (DIMS), Highly Aspherical Lenslets (HAL), and Cylindrical Annular Refractive Elements (CARE), have emerged as primary management strategies. Unlike conventional single-vision lenses, DSLs utilize specific optical geometries to impose a myopic defocus on the peripheral retina to inhibit eye growth, while maintaining clear central vision. This narrative review synthesizes evidence from randomized controlled trials (RCTs), long-term extension studies, and real-world datasets published until late 2025. We critically evaluated the optical designs, clinical efficacy, fitting protocols, compliance determinants, and safety profiles. Converging evidence from pivotal RCTs demonstrates that DIMS and HAL designs reduce myopia progression and axial elongation by approximately 50-60% over 2-3 years compared to single-vision lenses. Long-term data extending to 6 years for DIMS and 5 years for HAL suggest sustained efficacy with minimal rebound observed upon discontinuation, although the evidence remains limited. Emerging designs utilizing alternative mechanisms, such as contrast modulation (Diffusion Optics Technology [DOT]) and geometric phase/quality variations (e.g., CARE), also show promising efficacy. Combination therapies, particularly DSLs with low-dose atropine, have shown additional benefits for rapid progressors. Nonetheless, real-world effectiveness is heavily dependent on compliance (targeting approximately 12 h/day) and precise fitting parameters. Currently, DSLs are a well-established, scalable, and generally safe approach for myopia control. Future clinical practice should prioritize rigorous fitting standards, objective compliance monitoring, and personalized treatment selection, based on individual progression risks and optical profiles.

INTRODUCTION

Uncorrected refractive error, primarily myopia, has evolved from a simple optical inconvenience into a leading cause of visual impairment worldwide. Epidemiological modeling paints a concerning picture: by 2050: nearly half of the global population is projected to be myopic, with approximately 10% suffering from high myopia [1]. This shift represents a looming public-health crisis, because high myopia is associated with an exponential increase in the risk of sight-threatening ocular pathologies, including myopic maculopathy, retinal detachment, primary open-angle glaucoma, and early-onset cataracts [2]. The socioeconomic burden associated with these complications is substantial, underscoring the urgent need for effective interventions in child hood, which is a critical period of refractive development.
For decades, the standard of care for juvenile myopia has been the use of single-vision lenses (SVLs) to correct distance acuity. Although effective for restoring vision, SVLs do not address the underlying progression of eye growth. Owing to the typically prolate shape of the myopic eye, SVLs often correct central vision while focusing peripheral light rays behind the retina, creating peripheral hyperopic defocus. Extensive research has implied that this hyperopic defocus can act as a stimulus for further axial elongation (AE), potentially accelerating myopia progression [3].
This understanding has catalyzed a paradigm shift from passive correction to active “myopia management.” The field has moved towards optical interventions designed to manipulate the visual environment of the retina. Defocused spectacle lenses (DSLs) utilize the retina's intrinsic ability to detect and respond to defocus signals. By utilizing novel optical geometries to impose myopic defocus (focusing light in front of the retina) or to modulate retinal contrast, these lenses aim to generate a “stop signal” for ocular growth while preserving high-quality central vision [4].
The landscape of myopia-control spectacle lenses has evolved rapidly from early experimental concepts to widely available clinical devices. Since the introduction of the pioneering lenslet-based defocus designs, including Defocus Incorporated Multiple Segments (DIMS) and Highly Aspherical Lenslets (HAL), the field has expanded to include additional optical strategies such as geometric refractive elements (e.g., Cylindrical Annular Refractive Elements [CARE]) and diffusion/contrast-modulation designs (e.g., Diffusion Optics Technology [DOT]). Clinicians are now faced with a complex array of optical designs and an expanding (yet sometimes fragmented) evidence base. This review synthesizes current randomized controlled trial (RCT) data, long-term outcomes (now extending to 6 years), and emerging real-world evidence (RWE) to provide a comprehensive, practical guide on lens design, fitting, compliance, and strategic implementation of myopia-control spectacle lenses in modern pediatric practice [5].

METHODS: LITERATURE SEARCH AND EVIDENCE SELECTION

A structured literature search was performed using PubMed, Web of Science, and Google Scholar from database inception to November 30, 2025. The searches combined DSL-related terms and representative designs (e.g., defocus spectacle lens, lenslet, peripheral defocus, DIMS, and HAL) with key outcomes (e.g., axial length/AE, spherical equivalent [SE], and myopia progression). Backward and forward citation tracking of key trials and recent reviews were used to identify additional studies and emerging lens technologies.
Clinical evidence in children and adolescents was prioritized (RCTs, extension/long-term follow-up studies, and well-described observational/real-world cohorts). Studies were included if they evaluated DSL interventions, reported axial and/or refractive outcomes, or provided actionable prescription information (fitting/centration, adaptation, and safety). Conference abstracts without sufficient methods, duplicates, and reports lacking relevant outcomes were excluded. Overlapping cohorts were handled by citing the most complete report with the longest follow-up. Given heterogeneity across designs and outcomes, results were synthesized narratively.

OPTICAL RATIONALE AND BIOLOGICAL MECHANISMS

The clinical efficacy of DSLs is not merely an optical phenomenon but is grounded in the complex biological homeostatic mechanism of emmetropization, where the eye modulates its axial growth rate to minimize perceived defocus.

Simultaneous competitive defocus

Modern DSLs, such as DIMS and HAL, operate on the principle of “simultaneous vision,” which is a significant departure from traditional bifocal or progressive lenses that provide distinct zones for different gaze angles. DSLs simultaneously present two distinct focal planes to the retina: a sharp focal plane on the retina (providing clear visual acuity) and a myopic defocus plane located anterior to the retina (serving as a growth inhibition signal) [6].
Animal models ranging from chicks to tree shrews and rhesus monkeys have been instrumental in elucidating this mechanism. These studies suggest that, when the retina receives competing defocus signals (i.e., clear and defocused images), the integration mechanism is non-linear. The retina often weighs the “stop” signal (myopic defocus) more heavily than the “grow” signal (hyperopic defocus), provided the myopic defocus covers a sufficient area of the visual field and reaches a requisite strength [7]. The location of this signal is critical; research indicates that defocus signals within the near periphery (approximately 10°-20° eccentricity) are potent regulators of central axial growth [8]. This finding implies that a lens design must ensure that the treatment zone covers this specific retinal area to be effective.
Biological validation of this optical theory has been performed in humans. Short-term exposure to these specific optical defocus signals has been shown to induce choroidal thickening, and a rapid physiological response is often considered a precursor biomarker for the long-term inhibition of scleral remodeling and eye growth. Studies using optical coherence tomography have detected measurable choroidal thickening in children wearing DIMS and HAL lenses after as little as 1 week, reinforcing the biological plausibility of the intervention [9,10].

Contrast modulation theory

Whereas most DSLs rely on dioptric defocus, DOT lenses employ distinct mechanisms. Instead of focusing light anterior to the retina, these lenses utilize thousands of microscopic scattering centers to create a controlled reduction in the retinal contrast. The “Contrast Theory” posits that the high-contrast visual environment typical of modern life (e.g., intense reading and digital screens) may over-stimulate specific bipolar cell pathways in the retina, particularly in the periphery, which is hypothesized to drive axial growth. By artificially reducing peripheral contrast by approximately 40-50% without altering the focal plane, these lenses aim to dampen this abnormal signaling cascade [11,12]. This diversity in successful mechanisms suggests that the emmetropization system is multifaceted, potentially processing "blur" through multiple distinct neural pathways―one detecting the sign of defocus and another analyzing the spatial frequency content of the image.

Accommodation and binocular interaction

Historically, a high accommodative lag (insufficient focusing during near work) was considered a primary driver of myopia under the hypothesis that it induced hyperopic retinal blur. Consequently, earlier designs, such as bifocals, aimed to reduce the accommodative demand. However, recent dynamic accommodation studies in children wearing modern DSLs (DIMS and HAL) have shown that these designs do not significantly alter accommodative amplitude or lag compared to SVLs [13,14]. This is a crucial finding, because it reinforces the hypothesis that the efficacy of DSLs is driven primarily by direct retinal optical signaling (the imposition of myopic defocus) rather than by mechanically altering the accommodative posture of the eye. This distinction simplifies prescribing DSLs, because it suggests that efficacy is not strongly dependent on a child’s baseline accommodative status; however, binocular vision should still be monitored to avoid decompensation in children with phoria [15].

LENS DESIGNS: MAJOR FAMILIES AND TECHNICAL SPECIFICATIONS

Understanding the specific optical architecture of each lens type is essential for clinical decision making and troubleshooting.

DIMS

The DIMS lens is characterized by a “honeycomb” structure. It features a central 9-mm clear zone for distance refractive correction. Surrounding this center is a treatment zone (approximately 33 mm in diameter) containing approximately 396-400 interconnected lenslets. Each lenslet is approximately 1.03 mm in diameter and provides a relative positive power of +3.50 D [16]. The varying arrangement of lenslets and the spaces between them ensure that, for any object viewed through the treatment zone, the retina receives a 50:50 ratio of clear (distance correction) to defocused (+3.50 D) light. This design aims to provide a stable, constant magnitude of myopic defocus regardless of eye movement or pupil size, creating a robust “stop” signal.

HAL

According to the manufacturer’s technical specifications, HAL technology employs 11 concentric rings containing 1021 contiguous aspherical lenslets surrounding a 9-mm clear central zone. The high asphericity of these lenslets has been proposed to generate a distributed myopic-defocus signal (often described conceptually as a volume of myopic defocus), rather than a single additional focal plane. In practice, the exact defocus distribution is expected to vary with factors such as the pupil size, optical centration, and gaze position. Clinically, a 1-year study of spectacle lenses with aspherical lenslets demonstrated a significant slowing of myopia progression compared to that with single-vision correction [17]. Moreover, lenslet configuration can influence short-term visual performance, underscoring the need to balance myopia-control optics with wearer acceptance and adaptation in routine practice [18]. In HAL designs, the HALs and their spatial density are designed to enhance the myopic-defocus signal and may slightly compromise image quality under low-contrast or off-axis viewing, which can present as transient blur, halos, or ghosting during early adaptation.

CARE

CARE lenses introduce a different geometric approach that utilizes concentric rings of cylindrical microstructures rather than spherical or aspherical point-focus lenslets. Unlike DOT, which relies on light scattering, CARE uses refractive optics to generate a distinct optical signal on the retina. The posterior surface of these lenses often incorporates free-form optimization that is designed to minimize oblique aberrations induced by eye rotation, ensuring that the intended power profile is maintained peripherally. The CARE portfolio is often stratified by age: designs for younger children (< 10 years) typically feature a smaller central zone (e.g., 7 mm) and a higher mean addition power (+4.60 D) to maximize efficacy, while designs for older children feature a larger central zone (e.g., 9 mm) and a softer addition (+3.80 D) to balance efficacy with visual comfort [19].

Emerging designs and innovations

Innovation in this area continues to accelerate. Newer designs explore asymmetry and phase modulation. Asymmetric Multipoint Defocus Technology accounts for the natural asymmetry of the retina, where nasal and temporal retinas may exhibit different growth rates and curvatures. These lenses apply differential defocus patterns to different quadrants of the lens and have shown high efficacy in early trials [20].
Next-generation DSL platforms have recently emerged, including an enhanced HAL design (“H.A.L.T. MAX”) and a second-generation DIMS architecture commercialized as an updated iteration of the original lenslet system. H.A.L.T. MAX increases lenslet power and asphericity to strengthen the treatment signal, with a randomized contralateral crossover trial demonstrating greater short-term axial length control than first-generation HAL lenses [21]. Similarly, the new DIMS iteration retains the original honeycomb concept but incorporates modifications to the peripheral lenslet distribution and treatment-zone geometry. While these developments signal a broader trend toward increasing optical signal strength and retinal coverage, published evidence remains preliminary, and long-term randomized data are needed to confirm the comparative efficacy across platforms.
Additionally, a disruptive finding has emerged from studies on Lenslet Array Integrated designs. Recent trials comparing positive-power lenslets (standard myopic defocus) with negative-power lenslets found that both designs significantly inhibited AE compared to SVLs [22]. This finding challenges the dogma that only positive (myopic) defocus inhibits growth and suggests that the retina responds to the presence of higher-order aberrations or specific spatial phase disruptions caused by the lenslets rather than to the sign of defocus alone. This opens new avenues for lens design that prioritize signal “noise” or disruption over simple dioptric power.

CLINICAL EFFECTIVENESS: FROM RCTs TO LONG-TERM OUTCOMES

Efficacy in RCTs

Recent reviews and RCTs have consistently shown that DSLs outperform SVLs in slowing the progression of myopia, supporting their growing role in routine clinical care. Reported effects over 2 years typically fall in the range of approximately 0.45- 0.55 D less SE progression and 0.28-0.35 mm less AE, depending on lens design and study population [15,23]. The key optical characteristics and short-term to mid-term efficacy outcomes of the major DSL designs are summarized in Table 1.

Long-term sustainability and safety

Because myopia management is a multiyear endeavor, longitudinal data are critical.

DIMS 6-year data

Lam et al. [24] reported the results of the longest continuous follow-up to date. Children wearing DIMS for 6 years maintained a mean myopia progression of -0.15 D/year and AE of 0.10 mm/year. Notably, these rates are comparable to physiological growth observed in non-myopic children, suggesting that the treatment effectively “normalizes” eye growth [24].

HAL 5-year data

Recent reports indicate a cumulative reduction of 1.75 D in refractive error and 0.72 mm in AE over 5 years. This magnitude of cumulative reduction is clinically profound, potentially keeping a child who would have developed high myopia (-6.00 D) within the moderate myopia range (-4.25 D) and thereby significantly lowering the lifetime pathology risk [25].
Regarding the “Rebound Effect”―a rapid acceleration of progression often seen after discontinuing high-concentration atropine―available discontinuation studies suggest minimal rebound for DSLs. Data indicate that when children stop wearing DSLs, their progression rates may revert to age-matched norms rather than exceeding them [26]. This finding has led to the hypothesis that optical interventions may facilitate more stable structural remodeling of the eye than pharmacological approaches, although the evidence remains limited and heterogeneous [24].

Combination therapies

For “fast progressors” (e.g., AL growth > 0.3 mm/year despite treatment) [4], monotherapy may be insufficient. The concept of “boosting” the treatment effect by combining optical and pharmacological modalities is gaining traction.
A European comparative study by Nucci et al. [27] evaluated DIMS spectacles, 0.01% atropine, and a combination of DIMS and 0.01% atropine for 12 months in children and adolescents. In the model-adjusted analysis, the combination group showed the smallest axial elongation (approximately 0.06 mm over 12 months), compared with approximately 0.09 mm in the DIMS-only and approximately 0.10 mm in the atropine-only groups (with the control group showing substantially greater elongation). These findings support the clinical rationale for combination therapy in patients at higher risk of progression and highlight the need for longer follow-up and consistent reporting of wear-time adherence [27]. The mechanism is hypothesized to be synergistic: atropine induces mild mydriasis (pupil dilation) and reduces accommodation, which may increase the surface area of the peripheral retina exposed to the myopic defocus from the lenslets and thereby enhance the “stop” signal strength.
Other novel combinations, such as DSLs with Repeated Low-Level Red Light (RLRL) therapy, have shown potential for actual axial shortening (negative growth) in some studies (-0.13 mm over 12 months), although the long-term safety of RLRL regarding retinal phototoxicity remains a subject of intense scrutiny [28].

REAL-WORLD EFFECTIVENESS AND COMPLIANCE

While RCTs represent best-case scenarios with motivated participants, RWE reflects clinical reality. Studies from diverse populations in Europe and China have confirmed that DSLs are effective in routine practice, although effect sizes are often slightly lower than those in RCTs owing to variable compliance and broader patient-inclusion criteria [29,30].

Critical role of compliance

Compliance is the single most significant determinant of real-world outcomes. A clear “dose-response” relationship is suggested across lenslet designs.

Threshold

Many studies have suggested that outcomes are significantly better with full-time wear. A commonly cited practical target is approximately 12 hours of daily wear [23].

Context of wear

Clinicians must emphasize that DSLs should be worn during near work (reading and screen use) and not just for distance activities. During near tasks, the eye may experience an accommodative lag that induces hyperopic defocus. The constant presence of lenslets ensures that myopic defocus competes with this hyperopic signal, even during intense near work.

Visual performance and adaptation

Adaptation to DSLs is generally rapid and uncomplicated. While the peripheral treatment zones introduce optical blur, most children adapt within 1 week. Visual symptoms such as peripheral blur, “ghosting,” or mild halos are typically transient [31]. From a safety standpoint, reported issues are predominantly visual-quality-related (e.g., ghosting/halos, low-contrast blur, or eyestrain) rather than ocular adverse events, and these issues are usually addressed through practical troubleshooting (e.g., verifying centration through primary gaze, stabilizing the frame, and optimizing vertex distance (VD) and pantoscopic tilt) rather than treatment cessation. While high-contrast visual acuity remains unaffected (0.00 logMAR), a slight reduction in low-contrast visual acuity (0.1- 0.3 logMAR) and peripheral contrast sensitivity is inherent to the optical design. However, studies on functional vision have shown that the DSL use does not impact daily activities, reading speed, or safety [32]. Short-term laboratory comparisons across lenslet configurations support that any decrements in visual performance are generally modest, design-dependent, and most evident under low-contrast or off-axis viewing conditions [18]. Recent research into mobility performance confirms that peripheral refractive errors induced by these lenses do not significantly impair navigation or object detection [33]. However, clinicians should monitor for potential secondary effects; some emerging evidence indicates that certain peripheral defocus designs might influence cylindrical error or astigmatism over time, possibly due to altered eyelid mechanics or corneal remodeling, although this remains to be confirmed [34]. To strengthen safety inference for evolving DSL designs, future trials and RWE studies should standardize adverse-event reporting (visual symptoms, adaptation timelines, and discontinuation reasons) and report cylinder change alongside axial and corneal/biometric measures.

A PRAGMATIC PRESCRIBING PATHWAY

Successful implementation requires more than simply prescribing a lens; it also requires a structured clinical pathway. A practical fitting and follow-up checklist for DSLs based on current evidence and expert consensus is outlined in Table 2.

Candidate selection

DSLs are suitable as first-line treatment for the vast majority of children with progressive myopia. Ideal candidates are those with onset < 10 years, a parental history of myopia, and documented rapid axial growth (e.g., ≥ 0.30 mm/year, age-adjusted) [4]. DSLs are particularly valuable for children who are intolerant to contact lenses or whose parents are hesitant about the side effects of atropine.

Fitting protocols

Precision is paramount. Unlike standard SVLs, where slight decentration is often tolerated, DSLs require submillimeter precision to align the central clear zone with the visual axis.

Centration

Monocular pupillary distance and fitting height must be measured using the “pupil center” reflection method rather than the corneal limbus method.

VD

VD should be minimized (ideally 10-12 mm). A larger VD reduces the field of view through the treatment zone, decreasing retinal exposure to the therapeutic defocus signal. Therefore, frame selection and adjustment should prioritize stable back-vertex positioning [35].

Pantoscopic tilt

A standard tilt of 8°-12° is recommended to maintain the alignment of the optical center with the center of rotation of the eye. Excessive tilt can induce unwanted aberrations and misalignments.

Frame selection

Frames must be stable, with adjustable nose pads to prevent sliding. A minimum frame height (B-dimension) of 30 mm is often required to ensure that the superior defocus zone is not cut off, which is critical to ensure that the treatment effect covers the upper visual field [36].

Monitoring and escalation

Follow-up should occur every 6 months and must include biometry (axial length) as the primary outcome measure.

Adaptation check

Clinicians should inquire about visual symptoms during the first follow-up visit. Transient “ghosting” or slight blur in the periphery is common in the first week. If symptoms persist for > 2 weeks, the fitting parameters (height and pantoscopic tilt) and frame stability should be rechecked.

Responders

Axial growth of < 0.1 mm/6 months is considered excellent control; in this case, current management should be continued.

Non-responders

Axial growth > 0.2 mm/6 months warrants investigation. Compliance and fitting accuracy should be assessed first. If fitting is optimal and compliance is high, “boosting” therapy should be considered: this involves the addition of adding low-dose atropine or stepping up to a clinically available DSL with a stronger treatment signal (e.g., within the same product platform selecting the higher-add/stronger lenslet option, a smaller central clear zone, or a denser lenslet distribution), while monitoring short-term visual tolerance and adaptation [4].

DISCUSSION: EVIDENCE GAPS AND FUTURE DIRECTIONS

Despite robust evidence, significant gaps remain in the literature. Head-to-head comparisons between different DSL designs (e.g., DIMS, HAL, and CARE) are scarce, making it difficult to recommend one specific design over another for individual phenotypes. Recent small-scale comparative studies suggest comparable efficacy, but large-scale trials are needed [37,38]. In addition, generalizability is constrained by region-specific cohorts and heterogeneous outcome reporting (e.g., follow-up schedules and analytical approaches), which complicates cross-study comparisons and indirect rankings of designs. Real-world effectiveness studies improve external validity but may be influenced by selection bias, confounding factors (including concurrent behavioral interventions), and imperfect adherence measurement (often parent-reported rather than objectively monitored). Industry involvement in parts of the evidence base underscores the need for independent replication and standardized reporting. Furthermore, the interaction between lens design and individual peripheral retinal refraction profiles must be explored. Future lenses might be customized to a child's specific retinal contour, optimizing the “dose” of defocus for their unique eye shape [39].
Another frontier is the prevention of myopia onset. A recent RCT in Chinese children with low hyperopia, a group considered at elevated risk of future myopia, evaluated spectacle lenses with HAL compared to SVLs. Over the study period, children assigned to the HAL group showed significantly less axial elongation and a smaller myopic shift in refraction, with a clear dose-response relationship (greater benefit among children who wore the lenses for longer weekly hours). These findings indicate that introducing lenslet-based optical designs before frank myopia develops may help slow pre-myopic axial growth and potentially delay myopia onset, representing a shift from “myopia control” toward risk-targeted myopia prevention; however, longer follow-up is required to confirm true onset-delay and durability of effect [40].

CONCLUSIONS

DSLs have transformed pediatric myopia care from passive correction to active disease management. With proven long-term efficacy in reducing axial elongation by approximately 60% and a high safety profile, DSLs represent a cornerstone of modern practice. However, clinical success depends on more than just the lens; it requires a holistic approach involving precise fitting, rigorous compliance monitoring, and timely integration of combination therapies for high-risk patients. As the evidence base matures, personalized protocols that match lens optical profiles to individual eye growth patterns will likely define the next generation of myopia control.

Notes

This work was supported by the Guangzhou Aier Eye Hospital Scientific Research Fund (GAZD2024003).

Conflicts of interest

The author has no conflicts to disclose.

Table 1.
Comparison of optical designs and clinical efficacy (based on 2024-2025 data)
Lens technology Mechanism Key optical feature 1-2 year SE control* 1-2 year AE control*
DIMS [16] Multi-segment myopic defocus +3.50 D lenslets; honeycomb array ~52% (2 year) ~62% (0.34 mm)
HAL [23] HAL VoMD ~67% (2 year; full-time wearers) ~60% (0.41 mm, full-time wearers)
CARE [19] Geometric defocus (refractive) Cylindrical rings; clear posterior focus ~21% (1 year) ~26% (0.09 mm)
DOT [11] Contrast modulation Light scattering micro-dots 74% / 59% (1 year; Test 1/Test 2) 0.15/0.10 mm (1 year; Test 1/Test 2)
AMDT [20] Asymmetric defocus Nasal/temporal asymmetry ~74% (1 year) ~51% (0.17 mm)

DIMS = Defocus Incorporated Multiple Segments; HAL = Highly Aspherical Lenslets; CARE = Cylindrical Annular Refractive Elements; DOT = Diffusion Optics Technology; AMDT = asymmetric multipoint defocus technique; SE = spherical equivalent; AE = axial elongation; VoMD = volume of myopic defocus.

* Efficacy percentages are relative to control groups wearing single-vision lenses and may vary by study population and compliance.

Table 2.
Clinical fitting checklist for defocus spectacle lenses
Parameter Standard requirement Clinical rationale
Centration Monocular PD & Height (Pupil center) Aligns the central clear zone with the visual axis to avoid ghosting.
Vertex distance ≤ 10-12 mm Maximizes the retinal area covered by the peripheral defocus treatment zone.
Pantoscopic tilt 8°-12° Maintains alignment of the optical center with the eye's center of rotation.
Frame height ≥ 30 mm (B-size) Ensures the superior defocus zone is not cut off, providing full treatment effect.
Stability Adjustable nose pads Prevents frame slippage which can misalign the treatment zone.
Review cycle Every 6 months Monitor AL growth (> 0.2 mm may require escalation).

PD = pupillary distance; AL = axial length.

REFERENCES

1) Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016;123:1036-42.
crossref pmid pmc
2) Flitcroft DI, He M, Jonas JB, et al. IMI - defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci 2019;60:M20-30.
crossref pmid pmc
3) Smith EL 3rd. Optical treatment strategies to slow myopia progression: effects of the visual extent of the optical treatment zone. Exp Eye Res 2013;114:77-88.
crossref pmid pmc
4) Gifford KL, Richdale K, Kang P, et al. IMI - clinical management guidelines report. Invest Ophthalmol Vis Sci 2019;60:M184-203.
crossref pmid
5) Singh NK, De Gracia P. Next-generation spectacle lenses for myopia control: optical designs, mechanisms, and clinical efficacy. J Clin Med 2025;14:7872.
crossref pmid pmc
6) Tse DY, Lam CS, Guggenheim JA, et al. Simultaneous defocus integration during refractive development. Invest Ophthalmol Vis Sci 2007;48:5352-9.
crossref pmid
7) Smith EL 3rd, Arumugam B, Hung LF, et al. Eccentricity-dependent effects of simultaneous competing defocus on emmetropization in infant rhesus monkeys. Vision Res 2020;177:32-40.
crossref pmid pmc
8) Benavente-Perez A, Nour A, Troilo D. The effect of simultaneous negative and positive defocus on eye growth and development of refractive state in marmosets. Invest Ophthalmol Vis Sci 2012;53:6479-87.
crossref pmid pmc
9) Huang Y, Zhang J, Li X, et al. Effect of myopic defocus on the retina and choroid and its interaction with defocus regions, diurnal rhythm, and accommodation. Ophthalmol Sci 2025;5:100773.
crossref pmid pmc
10) Paulasto L, Carré C, Loertscher M. The influence of highly aspherical lenslets on choroidal thickness and axial length. J Clin Med 2025;14:7059.
crossref pmid pmc
11) Rappon J, Chung C, Young G, et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). Br J Ophthalmol 2023;107:1709-15.
crossref pmid pmc
12) Wolffsohn JS, Gifford KL. Optical strategy utilizing contrast modulation to slow myopia. Ophthalmol Sci 2024;5:100672.
crossref pmid pmc
13) Norazman FNN, Mohd-Ali B, Syed Mohd Dardin SF, et al. Impact of wearing defocus incorporated multiple segments spectacle lenses for 12 months on accommodation and binocular functions in myopic children. Clin Optom (Auckl) 2025;17:327-38.
crossref pmid pmc pdf
14) Lin Z, Christaras D, Duarte-Toledo R, et al. Dynamic accommodation responses in subjects wearing myopia control spectacles modifying peripheral refraction. Invest Ophthalmol Vis Sci 2025;66:55.
crossref pmid pmc
15) Vitiello L, Lixi F, Calabresi V, et al. The role of spectacle lenses in the control and management of myopia progression: a narrative review. Life (Basel) 2025;15:1415.
crossref pmid pmc
16) Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol 2020;104:363-8.
crossref pmid pmc
17) Bao J, Yang A, Huang Y, et al. One-year myopia control efficacy of spectacle lenses with aspherical lenslets. Br J Ophthalmol 2022;106:1171-6.
crossref pmid pmc
18) Li X, Ding C, Li Y, et al. Influence of lenslet configuration on short-term visual performance in myopia control spectacle lenses. Front Neurosci 2021;15:667329.
crossref pmid pmc
19) Liu X, Wang P, Xie Z, et al. One-year myopia control efficacy of cylindrical annular refractive element spectacle lenses. Acta Ophthalmol 2023;101:651-7.
crossref pmid pdf
20) Wang M, Ma R, Kuang L, et al. Myopia control efficacy of asymmetric multipoint defocus technique spectacle lenses: one-year double-masked randomized controlled trial. Ophthalmology 2025;132:972-9.
crossref pmid
21) Nallour Raveendran R, Ong WS, Wong YL, et al. Effect of increased power and asphericity of highly aspherical lenslets on myopia control efficacy: a contralateral crossover study. Transl Vis Sci Technol 2025;14:9.
crossref pmid pmc
22) Su B, Cho P, Vincent SJ, et al. Two-year results of Lenslet-ARray-Integrated spectacle lenses for myopia control in children. Eye Vis (Lond) 2025;12:45.
crossref pmid pmc pdf
23) Bao J, Huang Y, Li X, et al. Spectacle lenses with aspherical lenslets for myopia control vs single-vision spectacle lenses: a randomized clinical trial. JAMA Ophthalmol 2022;140:472-8.
crossref pmid pmc
24) Lam CSY, Tang WC, Zhang HY, et al. Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. Sci Rep 2023;13:5475.
crossref pmid pmc pdf
25) Li X, Huang Y, Liu C, et al. Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 5-year follow-up study. Eye Vis (Lond) 2025;12:10.
crossref pmid pmc pdf
26) Chiu YC, Tsai PC, Lee SH, et al. Systematic review of myopia progression after cessation of optical interventions for myopia control. J Clin Med 2023;13:53.
crossref pmid pmc
27) Nucci P, Lembo A, Schiavetti I, et al. A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS/atropine. PLoS One 2023;18:e0281816.
crossref pmid pmc
28) Luo CK, Lai CY, Tan JH, et al. Efficacy of repeated low-level red-light therapy combined with defocus incorporated multiple segments spectacles for controlling childhood myopia. Photodiagnosis Photodyn Ther 2025;54:104681.
crossref pmid
29) Liu J, Lu Y, Huang D, et al. The efficacy of defocus incorporated multiple segments lenses in slowing myopia progression: results from diverse clinical circumstances. Ophthalmology 2023;130:542-50.
crossref pmid
30) Najji R, Bullimore M, Resnikoff S, et al. The real-world effectiveness of defocus incorporated multiple segments and highly aspherical lenslets on myopia control: a longitudinal study from the French myopia cohort. BMJ Open Ophthalmol 2025;10:e002142.
crossref pmid pmc
31) Lu Y, Lin Z, Wen L, et al. The adaptation and acceptance of defocus incorporated multiple segment lens for chinese children. Am J Ophthalmol 2020;211:207-16.
crossref pmid
32) Gao Y, Lim EW, Drobe B. Impact of myopia control spectacle lenses with highly aspherical lenslets on peripheral visual acuity and central visual acuity with peripheral gaze. Ophthalmic Physiol Opt 2023;43:566-71.
crossref pmid pdf
33) García-Pedreño C, Tabernero J, Benito A, Artal P. Impact of peripheral refractive errors in mobility performance. Invest Ophthalmol Vis Sci 2024;65:42.
crossref pmid pmc
34) Xu W, Li X, Zhang J, et al. The peripheral defocus designed spectacle lenses might increase astigmatism in myopic children. Transl Vis Sci Technol 2025;14:8.
crossref pmid pmc
35) Liu KKK, Zhang HY, Leung DKY, Lam CSY. Evaluation of the peripheral visual performance of DIMS spectacle lenses versus single vision lenses. Front Neurosci 2024;18:1460062.
crossref pmid pmc
36) Kaymak H, Graff B, Neller K, et al. [Myopia treatment and prophylaxis with defocus incorporated multiple segments spectacle lenses]. Ophthalmologe 2021 118:1280-6. German.
crossref pmid pmc pdf
37) Orešković I, Malenica Ravlić M, Knežević L, et al. One-year comparative evaluation of highly aspherical lenslets and horizontally asymmetric peripheral defocus lenses for myopia control in school-aged children. Life (Basel) 2025;15:1119.
crossref pmid pmc
38) Han X, Zhang Y, Jin L, et al. One-year myopia control efficacy of a new defocus spectacle lens: a randomized clinical trial. Ophthalmol Sci 2025;6:100940.
crossref pmid pmc
39) Lupon M, Nolla C, Cardona G. New designs of spectacle lenses for the control of myopia progression: a scoping review. J Clin Med 2024;13:1157.
crossref pmid pmc
40) Zhang Z, Zeng L, Gu D, et al. Spectacle lenses with highly aspherical lenslets for slowing axial elongation and refractive change in low-hyperopic chinese children: a randomized controlled trial. Am J Ophthalmol 2025;269:60-8.
crossref pmid
TOOLS
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 2,735 View
  • 55 Download
Related articles


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
Korea University Anam Hospital, 73 Inchon-ro, Seongbuk-gu, Seoul 02841, Korea
Tel: +82-2-2266-7397    Fax: +82-2-2277-5194    E-mail: journal@annocl.org                

Copyright © 2026 by The Korean Optometry Society and The Korean Contact Lens Study Society.

Developed in M2PI

Close layer
prev next